IVI Urges Patient- and Family-Centered Approach to Drug Pricing Reform
Comments to Senate Finance Committee call for a U.S.-specific framework that aligns affordability, access, and innovation around the outcomes that matter to patients and families. IVI submitted comments to Senate Finance Committee Ranking Member Ron Wyden urging policymakers to address lower prescription drug prices, reduced patient out-of-pocket costs, and sustained biopharmaceutical innovation as interconnected goals—not […]
IVI Releases Executive Summary of its Patient-Centered Economic Impacts Workshop Series
IVI has released an executive summary from its Patient-Centered Economic Impacts initiative, capturing insights from a six-part workshop series exploring financial and time burdens faced by patients and caregivers. The findings highlight a critical gap: many of these impacts remain unmeasured in research and decision-making. The executive summary and individual learning reports focus on how […]
7th Annual Methods Summit — Summary Report
The 7th Annual Methods Summit was held on March 25, 2026 at the USC Capital Campus in Washington, D.C. The event convened leaders in value research, policy, and patient advocacy to examine how value assessment can better reflect the full spectrum of what matters to patients. Grounded in IVI’s principles of methodological rigor, transparency, equity, […]
New Video: Rare Disease Patient Engagement Checklist
IVI has released a new video introducing the Rare Disease Patient Engagement (RDPE) Checklist, a practical framework designed to help researchers embed patient and caregiver perspectives across all phases of rare disease value research and assessment. The video highlights why meaningful engagement matters, how lived experience strengthens evidence generation, and practical steps research teams can […]
IVI at ISPOR 2026
IVI will participate in ISPOR 2026 through poster presentations and invited panel discussions focused on patient-centered value assessment, outcomes research, methodological innovation, and healthcare decision-making. Throughout the conference, IVI researchers and collaborators will share work spanning rare disease patient engagement, mental health outcomes research, machine learning applications, and broader discussions on equity and patient-reported outcomes. […]
New in AJMC: Prioritizing Patient-Centered Value Over International Reference Pricing in U.S. Drug Policy
IVI is pleased to share a new commentary published in the AJMC® Contributor Column: “Prioritizing Patient-Centered Value Over International Reference Pricing in U.S. Drug Policy,” by Dominique Seo, MPH; Panos Kanavos, PhD; Eleanor M. Perfetto, PhD, MS; and Tiffany Huth, MPH. As policymakers consider international reference pricing (IRP) and most-favored nation (MFN) models as tools […]
IVI Announces the Appointment of Five New Board Members
IVI (IVI), a non-profit research organization committed to advancing the science, practice, and use of value assessment in healthcare announced the addition of five new members to its 2026 Board of Directors: Elizabeth Cope, PhD, MPH (Chief Programs & Science Officer, AcademyHealth), Amy Duhig, PHD (Senior Director, New Product Planning, Value and Evidence Generation, Takeda […]
IVI Calls for Stronger Patient Partnership and Real Consideration of Novel Value Elements in HEMA’s Draft Methods Report
In its public comments on the Health Economics Methods Advisory (HEMA) group’s draft report, “Defining Appropriate Benefits for Economic Evaluation of Health Care Technologies,” the IVI urged HEMA to strengthen its framework for defining benefits in economic evaluation. IVI called for patients and caregivers to be engaged as co-creators in methods development, for equity to […]
IVI Comments on the CMS Draft Guidance for the Medicare DPNP
IVI submitted comments on the draft guidance on the Medicare Drug Price Negotiation Program published on May 12, 2025.
IVI Responds to MFN Executive Order
Advancing patient-centered, evidence-based policy Alexandria, VA – May 13, 2025 – IVI released the following statement: IVI shares the goal of ensuring patients have affordable access to needed therapies. Controlling healthcare costs is essential to maintaining that access. However, the Most Favored Nation (MFN) pricing model is a blunt instrument that imports foreign price controls […]